No 11 - 2010
Foreign travel: Phone guidance
Form 1515 error
Need for HIV testing after risk situations, clarification
Holland: Q-fever outbreak
As from 1 May 2010, only the electronic version of EPI-NYT (the Danish version of EPI-NEWS) will be published. The reasons for this change include the considerable postage expenses and the general trend towards electronic communication. We hope readers will continue subscribing to EPI-NYT, which will continue to be available free of charge via E-mail.
(Department of Epidemiology)
Phone guidance on vaccination and Malaria prophylaxis in connection with foreign travel
As from 6 April 2010, the health staff guidance service on vaccination and malaria prophylaxis in connection with foreign travel will be open on working days 8.30-11.00 AM and 2-3 PM. Phone: +45 32 68 30 38.
The services are now managed jointly with the other guidance services provided by the Department of Epidemiology. Also feel free to contact the service via E-mail: email@example.com.
Before submitting your request, we recommend that you see ”Rejser og smitsomme sygdomme” (in Danish language) at www.ssi.dk/rejser and/or the latest issue of EPI-NEWS containing vaccination recommendations for foreign travel, EPI-NEWS 26 a+b/09.(Department of Epidemiology)
Error on form 1515
The Department of Epidemiology has become aware of an error on the reverse of the National Board of Health form 1515 which is used for individual notification of infectious diseases. Specifically, the error is found on forms labelled with no. 80232311 from October 2007.
On the reverse of the form, the name of the disease, notification criteria and microbiological agent/serological markers are stated. In the section describing "purulent meningitis", the subsection on microbiological agent/serological markers states "Neisseria meningitidis". The correct text is "Detected microorganisms". All cases of purulent meningitis are notifiable, not just meningitis caused by Neisseria meningitidis, cf. executive order no. 277 of 14 April 2000 with subsequent amendmends published by the National Board of Health. We regret this error which will be corrected in future reprints of the form.
(Department of Epidemiology)
Clarification of need for HIV testing after ris situation
EPI-NEWS 46/09 comments on the National Board of Health's new strategy on health staff's duty to actively offer HIV testing to anyone at special risk of infection. For persons actively requesting an HIV test, it was stated that testing should take place immediately in connection with the request and not, as previously, at a certain interval after the risk situation occurred, the so-called window phase. Persons requesting a test may be informed that the majority of those infected test positive very quickly and that a negative result in the now widely used combitest is reliable already four weeks after exposure; the corresponding period for modern antibody tests is eight weeks. It should be stressed that unless a patient presents with symptoms of acute HIV infection, the National Board of Health does NOT recommend a re-test after an additional two months, provided the blood sample is HIV-negative one month after an unequivocal risk exposure situation.
(Danish National Board of Health)
Holland: Q-fever outbreak
Q-fever is a zoonosis caused by the Coxiella burnetii bacterium, EPI-NEWS 46/06 and 03/09. The bacterium is primarily found in cattle, sheep and goats, and may provoke abortion. In infected animals, the bacteria accumulate frequently in large quantities in the placenta, but they are also to some degree excreted in urine, milk and faeces. The route of human infection is primarily airborne via aerosoles or dust from infected material. The incubation period for humans varies from two days to three weeks. Human-to-human infection with Q-fever does not occur; however, the placenta of infected pregnant women is highly infectious.
Outbreaks in Holland
In Holland, the number of patients recorded with Q-fever has increased drastically in recent years from 17 annual cases in the 1978-2006 period to 168 in 2007, 1,000 in 2008, 2,357 in 2009 and 225 by March 2010. Most patients are residents of Noord Brabant, a region with intensive goat farming. Approx. 30% of the goat farms test positive and the outbreak is attributed to an unusual combination of high population density, intensive goat farming, and, possibly, also a more virulent subtype of C. burnetii than the types prevalent in e.g. cattle.
The Dutch authorities have implemented a number of measures to control the outbreak. In goat farms with more than 50 milk-producing sheep or goats, the following measures are in place: mandatory vaccination of all animals, Q-fever tests performed routinely on tank milk samples, and breeding restrictions. In December 2009, all pregnant milk-producing goats were destroyed in such farms where tank milk samples tested positive. Manure from such farms shall be covered and stored for a period of 90 days prior to field manuring.
Q-fever occurrence in neighbouring countries
As C. burnetii may spread from 500 to 5,000 metres from an infected farm, there is a risk that the Dutch outbreak may spread to other regions. Consequently, exporting live goats from Holland is prohibited by law. 2008 saw an increase in the number of human Q-fever cases in Germany. This increase located in Southern Germany is compatible with regular fluctuations in the incidence of Q fever in Germany. In Belgium, which also borders on Germany, no increase in Q-fever has been observed in humans or animals.
It is essential to keep Q-fever in mind when considering differential diagnoses in persons presenting with symptoms consistent with Q-fever, who have visited Holland. It is particularly important if such persons have stayed in Noord Brabant. Q-fever may present in the form of influenza-like symptoms, pneumonia, hepatitis or endocarditis in those who have a predisposition. Q-fever can cause abortion in pregnant women. Particular attention should be given to persons with an increased risk of developing a chronic infection during the aftermath of the acute infection, e.g. immunosuppressed patients, persons with structural cardiovascular malformations (cardiac valve conditions, vascular prostheses) and pregnant women, EPI-NEWS 46/06 and 51/07.
(S. Bacci, P. Valentiner-Branth, K. Mølbak, Dept. of Epidemiology, S. Villumsen, Dept. of Microbiol. Surv. & Research)
17 March 2010